Summer Xia, Hasten Biopharma CEO
Chinese biotech startup adds $315M to the bank after bringing 5 Takeda drugs to its fold
More than two years after arriving on the China biopharma scene with a $322 million deal for five of Takeda’s drugs, Hasten Biopharma has landed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
